EFEMP1

Across TCGA pan-cancer cohorts, EFEMP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EFEMP1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EFEMP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EFEMP1 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and LSCC are the cancer types where EFEMP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	36	view →
LUAD	DFS	Median	II,III,IV	0.685	0.971	.004	30	view →
LSCC	OS	Median	II,III,IV	0.881	1.000	.014	14	view →
HNSC	OS	Tertile	IV	0.671	0.914	.017	5	view →
GBM	OS	Median	All	0.776	0.931	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EFEMP1–CCRCC (OS)

Open the CCRCC breakdown →